Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program

Phase I/II Trial Of FMC-376 Enrolled First Patient

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.